Mohamed Ahmed S, Awwad Ahmad R, Chacko Angel Ann, Dey Shraboni, Braithwaite Brianna, Bhuju Ruchi, Elias Sameh
Department of Internal Medicine, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Transitional Year Program, Hackensack Meridien Health, Palisades Medical Center, North Bergen, NJ 07047, USA.
Curr Oncol. 2025 Mar 10;32(3):156. doi: 10.3390/curroncol32030156.
This case report presents a rare occurrence of adrenal insufficiency induced by Zytiga (abiraterone acetate) in a patient with high-risk localized prostatic adenocarcinoma. Abiraterone acetate is a potent, selective and irreversible CYP17A1 inhibitor and is commonly used in the treatment of prostate cancer, but it can cause various endocrine side effects, especially if not used concurrently with the appropriate treatment. The clinical implications of this adverse event and management strategies are discussed here in this case report to raise awareness about this potential risk in patients with prostate cancer undergoing treatment with abiraterone acetate, especially when used in an erroneous manner without monitoring.
本病例报告展示了在一名高危局限性前列腺癌患者中，泽珂（醋酸阿比特龙）诱发肾上腺功能不全的罕见病例。醋酸阿比特龙是一种强效、选择性且不可逆的CYP17A1抑制剂，常用于治疗前列腺癌，但它会引起各种内分泌副作用，尤其是在未与适当治疗同时使用时。本病例报告讨论了这一不良事件的临床意义及管理策略，以提高正在接受醋酸阿比特龙治疗的前列腺癌患者对这一潜在风险的认识，特别是在错误使用且未进行监测的情况下。
